A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy (LIST)

Bristol-Myers Squibb (BMS)

Status

Completed

Conditions

Lung Cancer

Study type

Observational

Funder types

Industry

Identifiers

CA209-7HX

Details and patient eligibility

About

The purpose of this trial is to describe the following, for each cohort, in real world conditions in France:

The characteristics and treatment sequence of patients treated with nivolumab
The effectiveness of nivolumab treatment
The safety profile of nivolumab
Treatment patterns (e.g. duration of treatment, subsequent treatments) of nivolumab
The patient-reported outcomes (PRO) in patients treated with nivolumab, at baseline and during follow up using the EuroQoL-5D-3L

Enrollment

535 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

Pathologically confirmed diagnosis of advanced NSCLC
Whose physician has already decided to initiate a treatment with nivolumab for the treatment of advanced NSCLC according to the European label
Previously treated with at least one prior chemotherapy- containing regimen

Exclusion Criteria:

Participants taking part in an interventional study for lung cancer treatment for which nivolumab is one of the investigational drugs
Participants with a diagnosis of another primary cancer within the past five years
Participants receiving IO within 12 weeks prior to nivolumab first infusion in the context of the present study

Other protocol-defined inclusion/exclusion criteria apply